146 related articles for article (PubMed ID: 34250423)
21. Prevalence of pathogenic germline variants in the circulating tumor DNA testing.
Yamamoto Y; Fukuyama K; Kanai M; Kondo T; Yoshioka M; Kou T; Quy PN; Kimura-Tsuchiya R; Yamada T; Matsumoto S; Kosugi S; Muto M
Int J Clin Oncol; 2022 Oct; 27(10):1554-1561. PubMed ID: 35870019
[TBL] [Abstract][Full Text] [Related]
22. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
23. Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring.
Hallermayr A; Benet-Pagès A; Steinke-Lange V; Mansmann U; Rentsch M; Holinski-Feder E; Pickl JMA
Clin Chem; 2021 Nov; 67(11):1483-1491. PubMed ID: 34392332
[TBL] [Abstract][Full Text] [Related]
24. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
Fernandez SV; Tan YF; Rao S; Fittipaldi P; Sheriff F; Borghaei H; Dotan E; Winn JS; Edelman MJ; Treat J; Judd J; Alpaugh RK; Wang YL; Yu JQ; Wasik M; Baldwin DA
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958763
[TBL] [Abstract][Full Text] [Related]
25. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
26. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Plagnol V; Woodhouse S; Howarth K; Lensing S; Smith M; Epstein M; Madi M; Smalley S; Leroy C; Hinton J; de Kievit F; Musgrave-Brown E; Herd C; Baker-Neblett K; Brennan W; Dimitrov P; Campbell N; Morris C; Rosenfeld N; Clark J; Gale D; Platt J; Calaway J; Jones G; Forshew T
PLoS One; 2018; 13(3):e0193802. PubMed ID: 29543828
[TBL] [Abstract][Full Text] [Related]
27. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
28. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
[TBL] [Abstract][Full Text] [Related]
29. A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.
Shah AT; Azad TD; Breese MR; Chabon JJ; Hamilton EG; Straessler K; Kurtz DM; Leung SG; Spillinger A; Liu HY; Behroozfard IH; Wittber FM; Hazard FK; Cho SJ; Daldrup-Link HE; Vo KT; Rangaswami A; Pribnow A; Spunt SL; Lacayo NJ; Diehn M; Alizadeh AA; Sweet-Cordero EA
Mol Cancer Ther; 2021 Oct; 20(10):2016-2025. PubMed ID: 34353895
[TBL] [Abstract][Full Text] [Related]
30. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
31. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
32. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
33. Landscape of circulating tumour DNA in metastatic breast cancer.
Davis AA; Jacob S; Gerratana L; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Cristofanilli M
EBioMedicine; 2020 Aug; 58():102914. PubMed ID: 32707446
[TBL] [Abstract][Full Text] [Related]
34. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
36. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
[TBL] [Abstract][Full Text] [Related]
37. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract][Full Text] [Related]
38. Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.
Lee KS; Seo J; Lee CK; Shin S; Choi Z; Min S; Yang JH; Kwon WS; Yun W; Park MR; Choi JR; Chung HC; Lee ST; Rha SY
Clin Chem; 2022 Dec; 68(12):1519-1528. PubMed ID: 36306340
[TBL] [Abstract][Full Text] [Related]
39. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
40. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
